Literature DB >> 21873760

[What happens when the child gets bacteriophage per os?].

K I Pagava, K K Gachechiladze, I A Korinteli, M G Dzuliashvili, Z I Alavidze, N Hoyle, G D Metskhvarishvili.   

Abstract

The aim of the work was to define the distribution of phages administered per os to children for medical reasons, and the immune response. 102 children aged from 5 days to 15 years with different diseases of bacterial etiology (pneumonia, sepsis, urinary infection, pharyngitis/sinusitis, enteral infection) were monitored. Pyobacteriophage was being included into the complex therapy. The drug was administered per os. In 6/7 of blood, 48/55 urine and 64/75 stool samples taken on the 3-5th day of treatment different components of pyobacteriophage were revealed. The titers varied from 103 to 105 pfu/ml. No age differences were seen. In two weeks after the onset of the phagotherapy the antibodies to phages were tested in the blood serum using the neutralization reaction method. The blood samples were taken from 31 patients. In 14 of them the antibodies neutralizing 52.5-97.3% of the phage activity were seen. A significant age-related peculiarity was determined: in newborns and infants the antibodies were not revealed or their activity was low. Obtained results confirm the reasonability to use of peroral phagotherapy in gastro-intestinal infections. At the same time it was ascertained that the phages taken per os can permeate into the internal environment of the organism and thus the peroral phagotherapy can be used to treat systemic infections and urinary tract infections as well. Absence or low production of the antiphage antibodies in newborns and infants suggests high efficacy of the phagotherapy in this age group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873760

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  4 in total

Review 1.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

2.  Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome.

Authors:  Pikria Zhvania; Naomi Sulinger Hoyle; Lia Nadareishvili; Dea Nizharadze; Mzia Kutateladze
Journal:  Front Med (Lausanne)       Date:  2017-07-03

Review 3.  Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.

Authors:  Krystyna Dąbrowska
Journal:  Med Res Rev       Date:  2019-03-19       Impact factor: 12.944

Review 4.  Applications for Bacteriophage Therapy during Pregnancy and the Perinatal Period.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Front Microbiol       Date:  2018-01-11       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.